Endocrine ConnectionsAnaplastic Thyroid Cancer: Genome-based Search for New Targeted Therapy Options

In the study,155 FDA-approved drugs with 136 potentially targetable genes were identified.
One-hundred forty-six (94%) of the drugs showed no or low genetically predicted drug response. Although ATC-carrying BRAF mutations can benefit from BRAF inhibitors and this effect might be enhanced by a combined strategy including PIK3CA inhibitors in some of the patients, alterations in BRAFWT ATC are not directly targeted by currently FDA-approved options.